Bioequivalence study of two esomeprazole enteric coated formulations in healthy Chinese volunteers.
A bioequivalence study of two esomeprazole (CAS 119141-88-7) enteric-coated formulations was carried out in 20 healthy Chinese volunteers according to a single dose, two-sequence, crossover randomized design. The two formulations were administered in two treatment days, separated by a washout period of 7 days. Blood samples were collected at specified time intervals over 10 h post-dosing. Plasma samples were separated and assayed for esomeprazole using a selective and sensitive HPLC method with UV detection. The pharmacokinetic parameters AUC(0-12h), AUCmax, Cmax, tmax, t1/2 and MRT were determined from the plasma concentration-time profile of both formulations. ANOVA and two one-sided t-test procedures showed no significant difference in log-transformed Cmax, AUC(0-12h) and AUC(0-infinity) while the 90% confidence interval (CI) of the ratio of the geometric means of their values were also used to assess bioequivalence between the two formulations. The results of this study indicated that the two esomeprazole formulations can be considered to be bioequivalent.
Department of General Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
Wei
W
Cai
Zheng-ting
ZT
Wang
Juan
J
Li
Jia-jia
JJ
Hu
Jie
J
Zhong
D019540:Area Under Curve; D044466:Asian People; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D002851:Chromatography, High Pressure Liquid; D018592:Cross-Over Studies; D064098:Esomeprazole / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D013608:Tablets, Enteric-Coated; D013810:Therapeutic Equivalency; D055815:Young Adult
D054328:Proton Pump Inhibitors; D013608:Tablets, Enteric-Coated; D064098:Esomeprazole